Sunday, October 4, 2026

USD/CNH Is 1% Down In The Last 10 Sessions

ViaNews Editorial Team

February 2, 2024

USD/CNH Is 1% Down In The Last 10 Sessions

(VIANEWS) - USD/CNH (USDCNH) has been up by 1.93% for the last 10 sessions. At 22:06 EST on Thursday, 1 February, USD/CNH (USDCNH) is $7.19.

USD/CNH's yearly highs and lows, it's 0.046% up from its 52-week low and 0.029% down from its 52-week high.

News about

  • According to FXStreet on Thursday, 1 February, "USD/JPY caught a slight bid to push the pair back into the 147.00 handle heading into the Thursday market session after USD/JPY traders got a workout thanks to Wednesday's outing from the US Federal Reserve (Fed) and Fed Chairman Jerome Powell."
  • According to DailyForex on Thursday, 1 February, "If the USD/JPY pair breaches this level, it would bring into play the 50-day Exponential Moving Average and eventually the 145 yen level. ", "In fact, the Japanese yen appears to be an unattractive asset for investors, irrespective of whether they are actively trading the USD/JPY pair. "
  • Usd/jpy catches a bid on static fed rate call, tests 146.80. According to FXStreet on Wednesday, 31 January, "The USD/JPY jostled in rough chart action after the Federal Reserve (Fed) left rates unchanged with additional cautionary concerns about needing the economic outlook to be more certain and better indicators that US inflation will fall to and stay at 2% moving forward."
  • According to DailyForex on Wednesday, 31 January, "Overall, the USD/JPY market maintains a general inclination towards an upward trajectory. "

More news about USD/CNH (USDCNH).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com